Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15682035 | 0.84 | CA2 (0.47) | TP53CA2CA1TSHRTUBB1 | |
| SCHEMBL10335833 | 0.84 | PDE4D (0.41) | TP53ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL3792065 | 0.80 | MAOB (0.42) | MAOBHIF1AEPAS1TP53CA2 | |
| SCHEMBL23537773 | 0.80 | MAOB (0.42) | MAOBHIF1AEPAS1TP53CA2 | |
| SCHEMBL18544403 | 0.80 | MAOB (0.42) | MAOBHIF1AEPAS1TP53CA2 | |
| SCHEMBL16368 | 0.79 | TP53 (0.64) | MAOBTP53CA2CA1TSHR | |
| SCHEMBL14882573 | 0.78 | MAPT (0.50) | HIF1AEPAS1TP53CA2CA1 | |
| SCHEMBL67875 | 0.78 | KDM4E (0.32) | TUBB1KDM4E | |
| SCHEMBL423475 | 0.77 | ALDH1A1 (0.46) | TUBB1ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL28038952 | 0.77 | ALDH1A1 (0.46) | TUBB1ALDH1A1HPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | claimed |
| EP-3189055-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2017-07-12 | — | — | EP | claimed |
| WO-2016034507-A1 | A PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-10 | — | — | WO | claimed |
| US-5087764-A | Deprotonation of a 1-substituted-2,3-difluorobenzene using an organometallic compound and reacting the reaction product with an electrophile | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 1992-02-11 | — | — | US | claimed |
| WO-2024133363-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| CN-111377925-B | Purine derivatives, preparation method thereof and application thereof in medicines | 四川科伦博泰生物医药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| EP-4306615-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| EP-4279565-A2 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4261267-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2023-10-18 | — | — | EP | disclosed |
| CN-113980686-B | Preparation method of lateral o-difluorobenzene liquid crystal compound containing cyclohexyl | 宁夏中星显示材料有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-110922306-B | Synthesis process of 2, 3-difluoro-4-alkoxyl phenol | 蚌埠中实化学技术有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3763802-B1 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008090140-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2008-07-31 | — | — | WO | disclosed |
| US-6670514-B2 | For use in liquid-crystal displays; having high absolute values of dielectric anisotropy combined with a favorable viscosity/ clearing point ratios | CLARIANT FINANCE (BVI) LIMITED (VG) | 2003-12-30 | — | — | US | disclosed |
| US-20030072894-A1 | For use in liquid-crystal displays; having high absolute values of dielectric anisotropy combined with a favorable viscosity/ clearing point ratios | CLARIANT GMBH | 2003-04-17 | — | — | US | disclosed |
| EP-0363458-B1 | 2,3-DIFLUOROBENZENES | MERCK PATENT GMBH (DE) | 1994-08-03 | — | — | EP | disclosed |
| US-5087764-A | Deprotonation of a 1-substituted-2,3-difluorobenzene using an organometallic compound and reacting the reaction product with an electrophile | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 1992-02-11 | — | — | US | disclosed |
| EP-0363458-A1 | 2,3-DIFLUOROBENZENES. | MERCK PATENT GMBH (DE) | 1990-04-18 | — | — | EP | disclosed |
| WO-1989008629-A1 | PROCESS FOR PREPARING 2,3-DIFLUOROBENZENES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072894-A1 | For use in liquid-crystal displays; having high absolute values of dielectric anisotropy combined with a favorable viscosity/ clearing point ratios | OCIAD2, HCFC1, OCIAD1 | MAOB 3179/4885HIF1A 2066/4885EPAS1 2408/4885 |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | MAOB 448/4885HIF1A 1475/4885EPAS1 1506/4885 |
| US-20170305912-A1 | PROCESS FOR THE PREPARATION OF 3-PHENYL/HETEROARYL-6-PHENOXY-8-ALKYLAMINO-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | TTBK1, TTK, TTBK2 | MAOB 1154/4885HIF1A 4227/4885EPAS1 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.